SCHEMBL335255

SCHEMBL335255

COC(C)Oc1ccc(Cl)c(C)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
PKM P14618 1/20 0.50
MCL1 Q07820 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.45
MAPT P10636 3/20 0.44
TP53 P04637 2/20 0.44
ALDH1A1 P00352 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MRGPRX4 Q96LA9 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10153913 0.84 KMT2A (0.53) KMT2AMEN1PKMMCL1SMN1; SMN2
SCHEMBL10359381 0.81 KMT2A (0.54) KMT2AMEN1PKMMCL1SMN1; SMN2
SCHEMBL900747 0.78 MCL1 (0.50) KMT2AMEN1PKMMCL1SMN1; SMN2
SCHEMBL30300758 0.78 MAPT (0.57) KMT2AMEN1PKMMCL1SMN1; SMN2
SCHEMBL14122577 0.78 MAPT (0.57) KMT2AMEN1PKMMCL1SMN1; SMN2
SCHEMBL14122441 0.78 MAPT (0.57) KMT2AMEN1PKMMCL1SMN1; SMN2
SCHEMBL13384229 0.78 MAPT (0.57) KMT2AMEN1PKMMCL1SMN1; SMN2
SCHEMBL130126 0.77 MCL1 (0.52) KMT2AMEN1PKMMCL1SMN1; SMN2
SCHEMBL2904091 0.77 TDP1 (0.72) KMT2AMEN1PKMMCL1SMN1; SMN2
SCHEMBL14122035 0.77 TDP1 (0.72) KMT2AMEN1PKMMCL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101296914-B Derivatives with PPAR agonist activity SHIONOGI & CO 2012-07-18 CN disclosed
US-8097610-B2 Derivative having PPAR agonistic activity SHIONOGI & CO., LTD. (JP) 2012-01-17 US disclosed
US-20090286974-A1 Derivative having ppar agonistic activity SHIONOGI & CO., LTD. (JP) 2009-11-19 US disclosed
CN-101296914-A Derivatives with PPAR agonist activity SHIONOGI & CO (JP) 2008-10-29 CN disclosed
EP-1939189-A1 DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY SHIONOGI & CO., LTD. (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286974-A1 Derivative having ppar agonistic activity PPARD, PPARA, PPARG KMT2A 1949/4885MEN1 4624/4885PKM 3490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.